. 2022 Oct 6;12(2):164–170. doi: 10.1007/s13730-022-00739-6

Table 3.

Summary of FSGS cases in acromegaly patients

Age/sex	Baseline renal function	Treatment	Renal function at final follow-up	References
46/M	sCr 0.8 mg/dL	Corticosteroid	sCr 1.2 mg/dL	[9]
	UP 8.2–15.0 g/day	Immunosuppressants	UP 1.0 g/day
		Surgical treatment
		LDL adsorption
		Somatostatin analogue
		ACEi
53/M	sCr 132 μmol/L	Surgical treatment	UP 2 +	[10]
53/M	UP 3 + ; 1.4 g/day	ACEi	UP 2 +	[10]
63/M	sCr 130.4 μmol/L	Corticosteroid	sCr 80.0 μmol/L	[11]
	sCr 130.4 μmol/L	Surgical treatment	UP 2.0 g/day
	UP 9.1 g/day	Surgical treatment	UP 2.0 g/day
64/M	cCr 0.6 mg/dL	Surgical treatment	UP 513 mg/day*	[12]
64/M	UP 967.3 mg/day*	ARB	UP 513 mg/day*	[12]
49/M	sCr 61 μmol/L	Corticosteroid	sCr 76 μmol/L	[13]
	UP 6.29 g/day	ARB, TAC, Tripterygium	UP 2.85 g/day
	UP 6.29 g/day	Surgical treatment	UP 2.85 g/day
74/M	sCr 1.34 mg/dL	Surgical treatment	sCr 1.53 mg/dL	Present case
74/M	UP 3.16 g/gCr	ARB	UP 0.7–1.0 g/gCr	Present case

M male, sCr serum creatinine, UP urinary protein, ACEi angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, TAC tacrolimus

^*Average of three examinations